Skip global navigation and go to header navigation

Skip global navigation and read the article

Skip global navigation and go to local navigation

Skip global navigation and go to footer navigation

Home > Corporate Profile > Corporate Governance

Corporate Governance

Enhancing Corporate Value through Management Transparency
Zeria is working to realize an agile management structure possessing management transparency and quick decision-making in terms of executing business wth the aim of enhancing its corporate value.

Corporate Governance Structure

Zeria is promoting various initiatives to enhance and improve corporate governance by designating the strengthening and reinforcement of corporate governance as a high priority management issue.

Meetings of the Board of Directors are held once a month, in principle, whereby critical issues are determined and the supervision of business execution is carried out based on detailed discussions and the open sharing of information. As of July 1, 2018, the Board of Directors consists of 12 Directors (of which two members are outside Directors) and four Audit & Supervisory Board Members (of which two members are outside Audit & Supervisory Board Members). Additionally, there are no conflicts of interest between the Company and its outside Directors and outside Audit & Supervisory Board Members.

Regarding its internal control system, at a meeting of the Board of Directors in May 2006, Zeria established its basic policy related to having a system firmly in place for ensuring appropriate business operations, including internal audits, information storage and risk management, and is working to ensure the effectiveness of the system.

In terms of the risks that are constantly envisioned in carrying out business, we are striving to establish and develop regulations by workflow based on the concept of building an organizational structure that is capable of managing within the workflow of each existing operational department. Specifically, we have a committee system in place to address items pertaining to the quality and safety of specific products as a pharmaceutical company and are addressing such issues horizontally through the Quality Control Committee, Safety Evaluation Committee and PL (Product Liability) Committee.

Corporate Governance Structure